Detalles de la búsqueda
1.
Pd-Catalyzed Decarboxylative Olefination: Stereoselective Synthesis of Polysubstituted Butadienes and Macrocyclic P-glycoprotein Inhibitors.
J Am Chem Soc
; 142(22): 9982-9992, 2020 06 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32352771
2.
YES1 amplification confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive cancer.
Br J Cancer
; 123(6): 1000-1011, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32572172
3.
Pharmacological characterization of TQ05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants.
Cancer Sci
; 110(10): 3306-3314, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31361380
4.
SHR-A1403, a novel c-mesenchymal-epithelial transition factor (c-Met) antibody-drug conjugate, overcomes AZD9291 resistance in non-small cell lung cancer cells overexpressing c-Met.
Cancer Sci
; 110(11): 3584-3594, 2019 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-31446643
5.
SHR-A1403, a novel c-Met antibody-drug conjugate, exerts encouraging anti-tumor activity in c-Met-overexpressing models.
Acta Pharmacol Sin
; 40(7): 971-979, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-30643210
6.
Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma.
Acta Pharmacol Sin
; 40(2): 268-278, 2019 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29777202
7.
Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.
Cancer Sci
; 109(4): 1207-1219, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-29446853
8.
STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer.
Cancer Sci
; 109(10): 3305-3315, 2018 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-30076657
9.
Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells.
Cancer Sci
; 108(7): 1458-1468, 2017 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-28388007
10.
AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
Biochem Biophys Res Commun
; 489(1): 14-20, 2017 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28536078
11.
Y-632 inhibits heat shock protein 90 (Hsp90) function by disrupting the interaction between Hsp90 and Hsp70/Hsp90 organizing protein, and exerts antitumor activity in vitro and in vivo.
Cancer Sci
; 107(6): 782-90, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-27002306
12.
Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.
Cancer Sci
; 105(1): 117-25, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24205792
13.
p38 mitogen-activated protein kinase is required for the antitumor activity of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid.
J Pharmacol Exp Ther
; 341(3): 709-17, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22414857
14.
Trastuzumab in combination with PEGylated interferon-α1b exerts synergistic antitumor activity through enhanced inhibition of HER2 downstream signaling and antibody-dependent cellular cytotoxicity.
Am J Cancer Res
; 12(2): 549-561, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35261786
15.
YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo.
Cancer Sci
; 102(7): 1374-80, 2011 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-21443688
16.
Third-generation EGFR inhibitor HS-10296 in combination with famitinib, a multi-targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR-mutant non-small cell lung cancer cells.
Thorac Cancer
; 12(8): 1210-1218, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33656275
17.
A modular biomimetic strategy for the synthesis of macrolide P-glycoprotein inhibitors via Rh-catalyzed C-H activation.
Nat Commun
; 11(1): 2151, 2020 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32358512
18.
1,4-Diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126) enhances the cytotoxicity of combretastatin A4 independently of mitogen-activated protein kinase kinase.
J Pharmacol Exp Ther
; 330(1): 326-33, 2009 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-19377096
19.
Synthesis and structure-activity relationship studies of cytotoxic anhydrovinblastine amide derivatives.
J Nat Prod
; 72(6): 1170-7, 2009 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-19499938
20.
p38 MAPK, but not ERK1/2, is critically involved in the cytotoxicity of the novel vascular disrupting agent combretastatin A4.
Int J Cancer
; 122(8): 1730-7, 2008 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18074350